Lexicon Pharmaceuticals
- LXRX
- NASDAQ
- Consumer Products
- Latest 2.19
- Currency US$
- Change 0.06
- Percent Change 2.817 %
- Volume 674,393
- Thu May 23, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 2.11
- Previous Close 2.13
- High 2.19
- Low 2.08
- Bidx0 --
- Askx0 --
- 52-week High 07/17 3.28
- 52-week Low 05/23 1.50
- Beta 1.872
- Market Cap 1,123.47M
- EPS -0.21
- P/E --
- Forward P/E --
- PEG --
- Annual Dividend --
- Yield --
News
- Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
- Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
- Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
- Lexicon to Report First Quarter Financial Results on May 10, 2013
- Lexicon To Present At The Needham Healthcare Conference
Financials & Calendars
- Sales $1,150,000
- Earnings $-106,310,000
- Return on Equity n/a
- Cash Flow --
- Cash $34,240,000
- Current Ratio 11.88
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $347,270,000
- Liabilities $105,060,000
- Liabilities-to-Equity Ratio 0.43
Price Ratios
- Price to Sales 976.93
- Price to Book 4.64
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 10 | $-0.05 | Aug 6 | $-0.02 |
| Surprises | Jul 31 | -16.67% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 24, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery.
Officers
- Raymond Debbane Chairman
- Arthur T. Sands, M.D., Ph.D. President; C.E.O. and Director
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
8800 TECHNOLOGY FOREST PLACETHE WOODLANDS, TX
77381
Phone: 2818633000
Fax: (281)-8638088
Ideas & Discussion
Live Discussion of LXRX on StockTwits